EGFR and non-small cell lung carcinoma: In summary, early-phase SBRT for the primary lung tumor combined with EGFR-TKI followed by RT may be an alternative choice for advanced NSCLC harboring the EGFR mutation, which has the potential to alter the course of disease progression and to delay targeted resistance, as well as increasing OS without serious AEs.